@article{8e383316afd646fe9dd2d28307205ca2,
title = "Oral gatifioxacin-induced ataxia [4]",
author = "N. Mohan and K. Menon and {Gurumadhva Rao}, P.",
note = "Cited By :5 Export Date: 10 November 2017 CODEN: AHSPE Correspondence Address: Mohan, N.; Department of Pharmacy Practice, College of Pharmaceutical Sciences, Shirdi Sai Baba Cancer Hospital, Manipal, Karnataka, 576 119, India; email: mohannidhi@rediffmail.com Chemicals/CAS: gatifloxacin, 112811-59-3, 180200-66-2; Anti-Infective Agents; Fluoroquinolones; gatifloxacin, 112811-59-3 References: McEvoy, G.K., (2001) AHFS drug information 2001, , Bethesda, MD: American Society of Health-System Pharmacists; Press, R.A., The use of fiuoroquinolones as anti infective transition therapy agents in community acquired pneumonia (2001) Pharmacotherapy, 21, pp. 100S-104S; Tarshis, G.A., Miskin, B.M., Jones, T.M., Once daily oral gatifioxacin versus oral levofioxacin in treatment of uncomplicated skin and soft tissue infections: Double blind, multicenter, randomized study (2001) Antimicrob Agents Chemother, 45, pp. 2358-2362; Lusbasch, A., Keller, I., Borner, K., Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafioxacin, levofioxacin trovafloxacin and moxifloxacin after single oral administration in healthy volunteers (2000) Antimicrob Agents Chemother, 44, pp. 2600-2603; Bertino, J., Fish, D., The safety profile of the fluoroquinolones (2000) Clin Ther, 22, pp. 798-817",
year = "2002",
language = "English",
volume = "59",
journal = "Bulletin. American Society of Hospital Pharmacists",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "19",
}